Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10736269 | 0.76 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1KDM4EEGFRKMT2A | |
| SCHEMBL10735118 | 0.75 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1KDM4EKMT2ANPSR1 | |
| SCHEMBL28515190 | 0.74 | ADORA2B (0.40) | SMN1; SMN2ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL29413036 | 0.74 | KAT2B (0.48) | ALDH1A1TDP1CYP3A4 | |
| SCHEMBL10741060 | 0.74 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1KDM4EKMT2ANPSR1 | |
| SCHEMBL1261585 | 0.71 | USP2 (0.58) | SMN1; SMN2ALDH1A1KDM4EKMT2ALMNA | |
| SCHEMBL23601680 | 0.71 | NPC1 (0.43) | SMN1; SMN2ALDH1A1EGFRKMT2ANPSR1 | |
| SCHEMBL7038026 | 0.70 | HPGD (0.41) | SMN1; SMN2ALDH1A1KDM4EKMT2ANPSR1 | |
| SCHEMBL3432687 | 0.70 | DPP4 (0.63) | ALDH1A1EGFRKMT2ANPSR1MEN1 | |
| SCHEMBL11045707 | 0.68 | CASR (0.47) | SMN1; SMN2ALDH1A1KDM4EEGFRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3825312-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Pharmasset LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3825312-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Pharmasset LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10603318-B2 | Inhibitors of hepatitis C virus | GILEAD PHARMASSET LLC (US) | 2020-03-31 | — | — | US | disclosed |
| US-10335409-B2 | Inhibitors of hepatitis C virus | GILEAD PHARMASSET LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-10335409-B2 | Inhibitors of hepatitis C virus | GILEAD PHARMASSET LLC (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3492464-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Sciences, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492464-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Sciences, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-2970335-B1 | MACROCYCLIC AND BICYCLIC INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-2970335-B1 | MACROCYCLIC AND BICYCLIC INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20190008858-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2019-01-10 | — | — | US | disclosed |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2014-01-16 | — | — | US | disclosed |
| WO-2014008285-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| WO-2014008285-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| EP-2618665-A1 | HCV NS3 PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130178413-A1 | HCV NS3 PROTEASE INHIBITORS | MSD ITALIA SRL (IT) | 2013-07-11 | — | — | US | disclosed |
| US-20130178413-A1 | HCV NS3 PROTEASE INHIBITORS | MSD ITALIA SRL (IT) | 2013-07-11 | — | — | US | disclosed |
| US-20130178413-A1 | HCV NS3 PROTEASE INHIBITORS | MSD ITALIA SRL (IT) | 2013-07-11 | — | — | US | disclosed |
| WO-2012040040-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178413-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, CTSC, GTF3C3 | SMN1; SMN2 4494/4885ALDH1A1 1179/4885KDM4E 2898/4885 |
| US-20190008858-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | SMN1; SMN2 4128/4885ALDH1A1 112/4885KDM4E 3280/4885 |
| US-10603318-B2 | Inhibitors of hepatitis C virus | HAVCR2, SLC10A1, GOT1 | SMN1; SMN2 4128/4885ALDH1A1 112/4885KDM4E 3280/4885 |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, LIPC | SMN1; SMN2 4556/4885ALDH1A1 200/4885KDM4E 2585/4885 |
| US-10335409-B2 | Inhibitors of hepatitis C virus | HAVCR2, SLC10A1, GOT1 | SMN1; SMN2 4128/4885ALDH1A1 112/4885KDM4E 3280/4885 |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | SMN1; SMN2 4128/4885ALDH1A1 112/4885KDM4E 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.